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Measurement of T-cell autoreactivity in autoimmune diabetes
Dear Sir, We sincerely applaud the organisers of the IDS-sponsored, first international T-cell workshop, who undertook and completed a very difficult task [1] . The purpose of this first T-cell workshop and its less ambitious successors, is to develop robust techniques for the measurement of T-cell autoimmunity in Type I (insulin-dependent) diabetes mellitus-prone subjects [2] . This would provide new mechanistic insight, improve staging of prediabetes and, eventually, allow us to measure the effectiveness of intervention therapies well before onset of overt disease. In this search for better procedure and technology, we all are still beginners. It took well over a decade to refine diabetes autoimmune serology to its present, quite reliable status. Autoantibodies could, however, be rather late markers of progressive autoimmunity, and the efforts to measure autoreactive Tcells in a disease principally mediated by T-cells are rational and important.
In the first workshop, 29 laboratories tested 24 diabetes-relevant antigens. It was probable that not all these antigens would be recognised equally by the diverse study cohorts of patients, relatives and unrelated control subjects, hence the variety of test antigens. One initial goal was to find, in a blinded protocol, culture conditions that allowed a distinction between control subjects and patients (and perhaps relatives), with a reasonable subset of antigens.
The data eventually generated were analysed with care. The results of this analysis were disappointing. Data analysis is, however, always influenced by certain basic assumptions and is often open to interpretations. When we received the workshop data, we concluded that, rather than none [1, 2], there were five laboratories (numbers 3, 8, 10, 15, 23) which could detect disease-associated T-cell responses to four to seven of the test antigens.
Some of these responses would have been excluded by the workshop data analysis team, due to their choice of a hard cut-off for positive responses. In our hands, the mean stimulation index of ovalbumin stimulated cells plus four standard deviations produced a cut-off for positive responses that distinguished positive patient from negative control subject responses to over ten`diabetes antigens' in blinded studies of several hundred patients, relatives and healthy controls [3] .
The Toronto-Pittsburgh collaborative team supplied two sets of T-cell response data to the workshop: those with and those without a small interleukin 2 (IL2) supplement. By the time of the T-cell workshop, we had garnered evidence, that abnormal T-cell anergy was common in diabetic patients and that T-cell responses were small but could be rescued by exogenous IL2 in our serum-free cultures [4] . This has since been substantiated [3, 5] .
Data from IL2-supplemented cultures were not evaluated by the workshop committee, because of confidentiality rules: IL2 supplements would have identified our laboratory. We acknowledge this rationale but as we all are still searching for basic assay alternatives, we here provide the data set from IL2-supplemented cultures, blindly submitted to the workshop years ago. Figure 1 shows the proportions of positive responses elicited by the test antigens. Incorporation of H 3 -thymidine in ovalbumin-stimulated and non-stimulated cultures was not statistically different (p values > 0.6). In this small data set IA2, ICA69 and some GAD65 preparations were most frequently targeted by diabetic autoimmunity.
Children with recent onset Type I diabetes (n = 10) generated 47 positive responses to the test antigens (not counting tetanus toxoid, TT), 16 were observed in the first-degree relative's (FDR) group (n = 3) and 3 were generated by the seven healthy control subjects (Fig. 1 insert) . The distinction of patients and healthy control subjects was significant (p < 0.0001, relative risk 10.97 [95 % CI 3.5±34.6]). Of the three first-degree relatives tested, two had responses to many of the test antigens, one did not, the former two are prospectively followed as part of a high risk relative's cohort [6] . Several workshop laboratories used first-degree relatives in their control group. Because relatives often show signs of diabetic autoimmunity, this could have contributed to a lack of distinction between patients and control subjects.
Serum-free culture systems with small IL2 supplements may be promising techniques for the detection of disease-associated T-cell autoreactivities in autoimmune diabetes. In our hands, T-cell autoreactivity without IL2 supplements is too variable for analysis. Other laboratories which use serum supplemented culture systems seem, however, to bypass some or much of the IL2 requirement, perhaps through cytokine release from bystander T-cells (e. g. [7, 8] Circulating hyaluronan and hyaluronidase are increased in diabetic rats
Dear Sir, Hyaluronan (hyaluronic acid) is a highly charged high-molecular-mass polyanion of repeating disaccharide units, found at its most in the extracellular matrix of loose connective tissue. Hyaluronan is implicated in various physiological functions including water and protein homeostasis, cell proliferation, cell locomotion and migration. Serum hyaluronan was found to be a marker of several diseases (hepatitis, primary bilary cirrhosis, rheumatoid arthritis, tumours and other diseases affecting connective tissue) [1] . Previous investigations have shown that patients with Type I (insulin-dependent) diabetes mellitus present a relative and absolute increase in hyaluronan in normal tunica media of arteries compared with non-diabetic subjects [2] . The aim of this study was to determine whether circulating hyaluronan was influenced by Type I diabetes in rats. With this information, one explanation for the enhanced deposition of hyaluronan in the tunica-media of diabetic patients could be provided.
To induce diabetes, a single injection of streptozocin (streptozocin crystallized, Boehringer, Mannheim, Germany; 45 mg/ Kg body weight) dissolved in normal saline with sodium citrate (0.02 mol/l, pH 4.5) was carried out through the exposed jugular vein. Control rats received an equivalent volume of the dissolving buffer alone. A group of diabetic rats received (once daily between 1700 and 1800 hours during 6 weeks) a subcutaneous injection of a fixed dose (6 U/rat) of a long-acting insulin (Lente MC, Novo, Paris, France) 7 weeks after injection of streptozocin. The number of rats used was 17 for non diabetics, 14 for non-treated diabetics and 12 for diabetics treated with insulin. Animals were killed by exsanguination and blood was collected for serum glucose, insulin and hyaluronan determinations and further analysis when it was necessary. All experiments were conducted in accordance with institutional guidelines and recommendations for the care and use of laboratory animals established by French Ministry of Agriculture (autorization No. 002245). Serum hyaluronan was quantified with an Peripheral blood mononuclear cells from children with recent onset Type I diabetes (n = 10, black bars), first-degree relatives (FDRs, n = 3, white bars) and healthy control subjects (n = 7, hatched bars) were cultured for 1 week in serum-free HL/ 1 medium before measurement of H 3 -thymidine incorporation. Cultures contained the workshop antigens (doses are in mg/ml where indicated) and 10 U/ml IL2. GAD, glutamate decarboxylase 65 kD, GAD(PEVKEG), possible mimicry (GAD/Coxsackievirus) peptide, bacGAD, baculovirus-expressed GAD, coliGAD, GAD expressed in E. coli, pDR4, GAD peptides able to bind to DR4 heterodimers, HSP, heat shock protein peptide 277, INS-pept, overlapping insulin peptides. Insert: individual positive proliferative responses to any of the test antigens (U) and the % of test antigens that evoked positive responses are shown Corresponding author: Dr. A. Chajara, UniversitØ de MØde-cine-Pharmacie, Laboratoire DIFEMA-MERCI, 22, Boulevard Gambeta, 76 000 Rouen, France
